

---

**Recommendation CM/Rec(2022)19  
of the Committee of Ministers to member States  
on establishing measures for the harmonised collection of activity data related to the  
availability and use of tissues and cells of human origin with a view to supporting self-  
sufficiency and facilitating international data sharing**

*(Adopted by the Committee of Ministers on 14 September 2022,  
at the 1442<sup>nd</sup> meeting of the Ministers' Deputies)*

---

The Committee of Ministers, under the terms of Article 15.b of the Statute of the Council of Europe (ETS No. 1),

Considering that the aim of the Council of Europe is to achieve greater unity between its member States and that this aim may be pursued, *inter alia*, by the adoption of common action in the health field;

Taking into account the right to protection of health, enshrined in the European Social Charter (ETS No. 035);

Having regard to the Convention for the protection of Human Rights and Dignity of the Human Being with regard to the application of Biology and Medicine: Convention on Human Rights and Biomedicine (ETS No. 164), in particular to Articles 10 and 19, and the Additional Protocol to the Convention on Human Rights and Biomedicine concerning Transplantation of Organs and Tissues of Human Origin (ETS No. 186);

Having regard to Resolution Res(78)29, adopted by the Committee of Ministers, on the harmonisation of legislation of member States relating to removal, grafting and transplantation of human substances and the final text of the 3<sup>rd</sup> Conference of European Health Ministers (Paris, 16-17 November 1987);

Recalling Recommendation CM/Rec(2020)5 of the Committee of Ministers to member States on the quality and safety of tissues and cells for human application;

Recalling Recommendation CM/Rec(2019)2 of the Committee of Ministers to member States on the protection of health-related data which replaces Recommendation Rec(97)5 of the Committee of Ministers to member States on the protection of medical data;

Recalling Resolution CM/Res(2015)11, adopted by the Committee of Ministers, on establishing harmonised national living donor registries with a view to facilitating international data sharing;

Recalling Parliamentary Assembly Recommendation 2173 (2020) on "Combating trafficking in human tissues and cells";

Taking into account the latest available edition of the Council of Europe Guide to the quality and safety of tissues and cells for human application;

Taking into account the World Health Organization (WHO) Guiding Principles on Human Cell, Tissue and Organ Transplantation as endorsed by the 63<sup>rd</sup> World Health Assembly in May 2010, in Resolution WHA63.22 on Human Organ and Tissue Transplantation, and in particular Guiding Principles 10 and 11, which call for health authorities to oversee that transplant programmes ensure traceability and vigilance and to monitor outcomes of both living donation and transplantation;

Taking into account the Madrid Resolution on Organ Donation and Transplantation, adopted in 2010, calling WHO member States to strive towards self-sufficiency in transplantation;

Considering Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells, and Commission Directive 2006/17/EC of 8 February 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for the donation, procurement and testing of human tissues and cells;

Considering Commission Directive 2006/86/EC of 24 October 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards traceability requirements, notification of serious adverse reactions and events and certain technical requirements for the coding, processing, preservation, storage and distribution of human tissues and cells, and in particular Article 5(1)(a) and Article 7;

Considering Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation), and in particular Article 9, paragraph 2, points (a), (h) and (i), which contain provisions permitting the processing of health data;

Taking into account the Barcelona Principles on the use of human donated tissue for ocular transplantation, research and future technologies;

Considering that human tissues and cells can restore essential functions or, in some cases, save lives;

Considering that achieving self-sufficiency based on voluntary unremunerated donation and security of supply, as well as timely and equitable access to safe transplantation, are important national (and European) goals to prevent shortages and meet the transplantation requirements of the patient population;

Considering that to ensure rational, fair, timely and equitable access to safe tissues and cells for human application, governments and donation and transplantation services need to know how many tissues and cells are available and how many are required for their populations so their needs can be met consistently and an appropriate level of funding to support donation programmes is maintained;

Considering that complete and accurate activity data related to the availability and use of tissues and cells of human origin would provide transparency for citizens and healthcare professionals;

Considering that complete activity data would be essential in order to avoid overreliance on countries outside of Europe or on a few European countries, as well as to prepare for risk scenarios that might impact supply;

Considering that this information would also be necessary to put into context the figures related to serious adverse events and reactions associated with the use of tissues and cells of human origin, which would allow the identification of trends and benchmarking of the performance of donation and transplantation programmes and tissue establishments with a view to maximising the quality and safety of tissues and cells for human application;

Aware that the increased transportation of tissues and cells between tissue establishments or even across national borders gives rise to difficulties in ensuring traceability, but that it is essential to maximise the safety and quality of donated tissues and cells and for ethical reasons;

Considering that the current picture of tissue and cell activity, whether for tissues and cells procured and distributed in individual member States or those exchanged at international level, is fragmented and incomplete;

Considering that, paradoxically, many stakeholders, including some member States and professional associations, are trying to collect activity data in this field, posing a significant burden on reporting bodies such as tissue establishments and clinical users, and that their efforts have been undermined by the lack of consensus and clarity on the data needed for different purposes and the heterogeneous terminology and units used to describe and quantify tissues and cells;

Considering that a common terminology would be required to ensure clarity on the data needed and the units used to describe and quantify tissue and cell availability and supply;

Recognising, therefore, the need to provide health authorities, transplant organisations, tissue establishments and organisations responsible for human application of tissues and cells, including clinical users, with a harmonised and common dataset to record activity data related to the availability and use of tissues and cells of human origin;

Considering that significant developments in IT solutions will help to ensure timely and regular data input and that technical developments will support data exchange between countries/regions,

Recommends that the governments of member States:

- having due regard to their national laws, rules and administrative provisions, take all necessary measures and steps to regularly collect activity data related to the availability and use of tissues and cells of human origin, taking into consideration the list of parameters and definitions shown in the appendix to this recommendation;
- translate, publish and disseminate widely this recommendation and its appendix among relevant national, regional, and local authorities, professionals, and other key stakeholders.

Authorises the Council of Europe European Committee on Organ Transplantation or, if necessary, a subordinate body, to revise the appendix to this recommendation in the future in keeping with developments in the field.

#### *Appendix to Recommendation CM/Rec(2022)19*

This appendix to Recommendation CM/Rec(2022)19 provides a list of the parameters member States should consider collecting and specifies how units should be counted. A supporting glossary of terms provides, where necessary, additional information clarifying how to measure or collect each parameter in a manner that will ensure accuracy and consistency and facilitate harmonised international data sharing. It should be noted that the glossary of terms should be used exclusively for the purpose of this data collection, as the definitions included might not be suitable for other purposes (e.g. during clinical practice). If a definition is not found among the terms included in this glossary, the Council of Europe Guide to the quality and safety of tissues and cells for human application should be used as a reference.

The set of variables and the glossary of terms are those developed within the framework of a co-operation Grant Agreement (GA 2018 53 01) between the European Commission and the EDQM/Council of Europe. Therefore, the terms and definitions used align with those of the relevant EU legislation. However, the data set may also prove valuable for non-EU Council of Europe member States with a view to supporting self-sufficiency and facilitating international data sharing.

The parameters detailed in the data set and the glossary of terms may be revised in the future in keeping with developments in the field.

### REPLACEMENT TISSUES ACTIVITY DATA

COUNTRY		Year	

  

DONORS (COLLECTED AT NATIONAL LEVEL)	NUMBERS	UNITS/EXPLANATIONS
DD Deceased donors		# of deceased tissue/cell donors at national level
LD Living donors		# of living tissue/cell donors at national level

  

OCULAR	OCULAR TISSUE		NUMBERS	UNITS/EXPLANATIONS
	OC 1	Living donors		# of living ocular tissue/cell donors at national level
	OC 2	Donors Deceased donors		# of deceased ocular tissue/cell donors at national level
	OC 3	Donations Ocular tissue donations		# of donation events from one donor, may include 1 or 2 eyes/comeas
	OC 4	Releases for clinical application, whether distributed or not	Cornea, full thickness (high endothelial cell density)	# of comeas with endothelial cell density $\geq$ 2000 cells per mm <sup>2</sup>
	OC 5		Cornea, full thickness (low endothelial cell density)	# of comeas with endothelial cell density < 2000 cells per mm <sup>2</sup>
	OC 6		Cornea for Endothelial Keratoplasty (precut/peeled in the Tissue Establishment)	# of comeas
	OC 7		Sclera	# of containers
	OC 8		Other ocular	# of containers
	OC 9	Distributed to end user in the country	Cornea, full thickness (high endothelial cell density)	# of comeas with endothelial cell density $\geq$ 2000 cells per mm <sup>2</sup>
	OC 10		Cornea, full thickness (low endothelial cell density)	# of comeas with endothelial cell density < 2000 cells per mm <sup>2</sup>
	OC 11		Cornea for Endothelial Keratoplasty (precut/peeled in the Tissue Establishment)	# of comeas
	OC 12		Sclera	# of containers
	OC 13		Other ocular	# of containers
	OC 14	Distributed to end user in another EU country	Cornea, full thickness (high endothelial cell density)	# of comeas with endothelial cell density $\geq$ 2000 cells per mm <sup>2</sup>
	OC 15		Cornea, full thickness (low endothelial cell density)	# of comeas with endothelial cell density < 2000 cells per mm <sup>2</sup>
	OC 16		Cornea for Endothelial Keratoplasty (precut/peeled in the Tissue Establishment)	# of comeas
	OC 17		Sclera	# of containers
	OC 18		Other ocular	# of containers
	OC 19	Sent to a tissue establishment (transport) in another EU country	Cornea, full thickness (high endothelial cell density)	# of comeas with endothelial cell density $\geq$ 2000 cells per mm <sup>2</sup>
	OC 20		Cornea, full thickness (low endothelial cell density)	# of comeas with endothelial cell density < 2000 cells per mm <sup>2</sup>
	OC 21		Cornea for Endothelial Keratoplasty (precut/peeled in the Tissue Establishment)	# of comeas
	OC 22		Sclera	# of containers
	OC 23		Other ocular	# of containers
	OC 24	Received from a tissue establishment (transport) in another EU country	Cornea, full thickness (high endothelial cell density)	# of comeas with endothelial cell density $\geq$ 2000 cells per mm <sup>2</sup>
	OC 25		Cornea, full thickness (low endothelial cell density)	# of comeas with endothelial cell density < 2000 cells per mm <sup>2</sup>
	OC 26		Cornea for Endothelial Keratoplasty (precut/peeled in the Tissue Establishment)	# of comeas
	OC 27		Sclera	# of containers
	OC 28		Other ocular	# of containers
	OC 29	Exports (non EU)	Cornea, full thickness (high endothelial cell density)	# of comeas with endothelial cell density $\geq$ 2000 cells per mm <sup>2</sup>
	OC 30		Cornea, full thickness (low endothelial cell density)	# of comeas with endothelial cell density < 2000 cells per mm <sup>2</sup>
	OC 31		Cornea for Endothelial Keratoplasty (precut/peeled in the Tissue Establishment)	# of comeas
	OC 32		Sclera	# of containers
	OC 33		Other ocular	# of containers
	OC 34	Imports (non EU)	Cornea, full thickness (high endothelial cell density)	# of comeas with endothelial cell density $\geq$ 2000 cells per mm <sup>2</sup>
	OC 35		Cornea, full thickness (low endothelial cell density)	# of comeas with endothelial cell density < 2000 cells per mm <sup>2</sup>
	OC 36		Cornea for Endothelial Keratoplasty (precut/peeled in the Tissue Establishment)	# of comeas
	OC 37		Sclera	# of containers
OC 38	Other ocular		# of containers	

OC 39	Application procedures	Applications for Penetrating Keratoplasty	# of applications (one surgical procedure, regardless of the # of grafts used)
OC 40		Applications for Anterior Lamellar Keratoplasty	# of applications (one surgical procedure, regardless of the # of grafts used)
OC 41		Applications for Endothelial Keratoplasty	# of applications (one surgical procedure, regardless of the # of grafts used)
OC 42		Applications for scleral reconstruction	# of applications (one surgical procedure, regardless of the # of grafts used)
OC 43		Applications for other ocular treatments (only use if the application does not fit into one of the above categories)	# of applications (one surgical procedure, regardless of the # of grafts used)

PLACENTAL TISSUE			NUMBERS	UNITS/EXPLANATIONS
PLACENTAL	PL 1	Donors	Living donors	# of living placental tissue donors at national level
	PL 2		Deceased donors	# of deceased placental tissue donors at national level
	PL 3	Donations	Placental membrane donations	# of donation events from one delivery, including multiple births
	PL 4	Releases for clinical application, whether distributed or not	Amniotic membrane	# of containers
	PL 5		Amniotic membrane eyedrops	# of batches prepared for a single patient
	PL 6		Other placental	# of containers
	PL 7	Distributed to end user in the country	Amniotic membrane	# of containers
	PL 8		Amniotic membrane eyedrops	# of batches prepared for a single patient
	PL 9		Other placental	# of containers
	PL 10	Distributed to end user in another EU country	Amniotic membrane	# of containers
	PL 11		Amniotic membrane eyedrops	# of batches prepared for a single patient
	PL 12		Other placental	# of containers
	PL 13	Sent to a tissue establishment (transport) in another EU country	Amniotic membrane	# of containers
	PL 14		Amniotic membrane eyedrops	# of batches prepared for a single patient
	PL 15		Other placental	# of containers
	PL 16	Received from a tissue establishment (transport) in another EU country	Amniotic membrane	# of containers
	PL 17		Amniotic membrane eyedrops	# of batches prepared for a single patient
	PL 18		Other placental	# of containers
	PL 19	Exports (non EU)	Amniotic membrane	# of containers
	PL 20		Amniotic membrane eyedrops	# of batches prepared for a single patient
	PL 21		Other placental	# of containers
	PL 22	Imports (non EU)	Amniotic membrane	# of containers
	PL 23		Amniotic membrane eyedrops	# of batches prepared for a single patient
	PL 24		Other placental	# of containers
	PL 25	Application procedures	Amniotic membrane applications for ocular treatment (excluding amniotic eye drops)	# of applications (one surgical procedure, regardless of the # of grafts used)
	PL 26		Amniotic membrane applications for ocular treatment (amniotic eye drops)	# of batches prepared for a single patient
	PL 27		Amniotic membrane applications for non-ocular burn/wound healing	# of applications (one surgical procedure, regardless of the # of grafts used)
	PL 28		Amniotic membrane applications for other treatments	# of applications (one surgical procedure, regardless of the # of grafts used)
	PL 29		Other placental tissue applications (only use if the application does not fit into one of the above categories)	# of applications (one surgical procedure, regardless of the # of grafts used)

CUTANEOUS TISSUE			NUMBERS	UNITS/EXPLANATIONS
CU 1	Donors	Living donors	# of living cutaneous tissue donors at national level	
CU 2		Deceased donors	# of deceased cutaneous tissue donors at national level	
CU 3	Donations	Skin donations	# of donation events from one donor, regardless of the number of tissues obtained	
CU 4	Releases for clinical application, whether distributed or not	Skin	cm <sup>2</sup>	
CU 5		Acellular dermal matrix	cm <sup>2</sup>	
CU 6		Keratocytes/melanocytes	# of containers	
CU 7	Distributed to end user in the country	Other cutaneous tissues	# of containers	
CU 8		Skin	cm <sup>2</sup>	
CU 9		Acellular dermal matrix	cm <sup>2</sup>	
CU 10		Keratocytes/melanocytes	# of containers	
CU 11		Other cutaneous tissues	# of containers	

<b>CUTANEOUS</b>	CU 12		Skin		cm2
	CU 13	<b>Distributed to end user in another EU country</b>	Acellular dermal matrix		cm2
	CU 14		Keratinocytes/melanocytes		# of containers
	CU 15		Other cutaneous tissues		# of containers
	CU 16	<b>Sent to a tissue establishment (transport) in another EU country</b>	Skin		cm2
	CU 17		Acellular dermal matrix		cm2
	CU 18		Keratinocytes/melanocytes		# of containers
	CU 19		Other cutaneous tissues		# of containers
	CU 20	<b>Received from a tissue establishment (transport) in another EU country</b>	Skin		cm2
	CU 21		Acellular dermal matrix		cm2
	CU 22		Keratinocytes/melanocytes		# of containers
	CU 23		Other cutaneous tissues		# of containers
	CU 24	<b>Exports (non EU)</b>	Skin		cm2
	CU 25		Acellular dermal matrix		cm2
CU 26	Keratinocytes/melanocytes			# of containers	
CU 27	Other cutaneous tissues			# of containers	
CU 28	<b>Imports (non EU)</b>	Skin		cm2	
CU 29		Acellular dermal matrix		cm2	
CU 30		Keratinocytes/melanocytes		# of containers	
CU 31		Other cutaneous tissues		# of containers	
CU 32	<b>Application procedures</b>	Applications for burns/wound healing		# of applications (one surgical procedure, regardless of the # of grafts used)	
CU 33		Applications for reconstructive surgery		# of applications (one surgical procedure, regardless of the # of grafts used)	
CU 34		Applications for other treatments (only use if the application does not fit into one of the above categories)		# of applications (one surgical procedure, regardless of the # of grafts used)	

<b>CARDIAC TISSUE</b>			<b>NUMBERS</b>	<b>UNITS/EXPLANATIONS</b>
CA 1	<b>Donors</b>	Living donors		# of living cardiac tissue donors at national level
CA 2		Deceased donors		# of deceased cardiac tissue donors at national level
CA 3	<b>Donations</b>	Cardiac tissue donations		# of donation events from one donor, regardless of the number of tissues obtained
CA 4	<b>Releases for clinical application, whether distributed or not</b>	HV, aortic		# of HV
CA 5		HV, pulmonary		# of HV
CA 6		HV, aortic decellularised		# of HV
CA 7		HV, pulmonary decellularised		# of HV
CA 8		Non-valved patches and conduits		# of containers
CA 9		Pericardium		# of containers
CA 10		Other heart tissues		# of containers
CA 11	<b>Distributed to end user in the country</b>	HV, aortic		# of HV
CA 12		HV, pulmonary		# of HV
CA 13		HV, aortic decellularised		# of HV
CA 14		HV, pulmonary decellularised		# of HV
CA 15		Non-valved patches and conduits		# of containers
CA 16		Pericardium		# of containers
CA 17		Other heart tissues		# of containers
CA 18	<b>Distributed to end user in another EU country</b>	HV, aortic		# of HV
CA 19		HV, pulmonary		# of HV
CA 20		HV, aortic decellularised		# of HV
CA 21		HV, pulmonary decellularised		# of HV
CA 22		Non-valved patches and conduits		# of containers
CA 23		Pericardium		# of containers
CA 24		Other heart tissues		# of containers

	CA	Description	Units	Comments	
					Units
CARDIAC	CA 25	HV, aortic		# of HV	
	CA 26	HV, pulmonary		# of HV	
	CA 27	HV, aortic decellularised		# of HV	
	CA 28	HV, pulmonary decellularised		# of HV	
	CA 29	Non-valved patches and conduits		# of containers	
	CA 30	Pericardium		# of containers	
	CA 31	Other heart tissues		# of containers	
	CA 32	HV, aortic		# of HV	
	CA 33	HV, pulmonary		# of HV	
	CA 34	HV, aortic decellularised		# of HV	
	CA 35	HV, pulmonary decellularised		# of HV	
	CA 36	Non-valved patches and conduits		# of containers	
	CA 37	Pericardium		# of containers	
	CA 38	Other heart tissues		# of containers	
	CA 39	HV, aortic		# of HV	
	CA 40	HV, pulmonary		# of HV	
	CA 41	HV, aortic decellularised		# of HV	
	CA 42	HV, pulmonary decellularised		# of HV	
	CA 43	Non-valved patches and conduits		# of containers	
	CA 44	Pericardium		# of containers	
	CA 45	Other heart tissues		# of containers	
	CA 46	HV, aortic		# of HV	
	CA 47	HV, pulmonary		# of HV	
	CA 48	HV, aortic decellularised		# of HV	
	CA 49	HV, pulmonary decellularised		# of HV	
	CA 50	Non-valved patches and conduits		# of containers	
	CA 51	Pericardium		# of containers	
	CA 52	Other heart tissues		# of containers	
	CA 53	Application procedures	Applications for HV replacement		# of applications (one surgical procedure, regardless of the # of grafts used)
	CA 54		Applications for cardiac reconstruction		# of applications (one surgical procedure, regardless of the # of grafts used)
	CA 55		Applications for other treatments (only use if the application does not fit into one of the above categories)		# of applications (one surgical procedure, regardless of the # of grafts used)

	VE	VESSELS	Units	Comments
VESSELS	VE 1	Donors	Living donors	# of living vessel donors at national level
	VE 2		Deceased donors	# of deceased vessel donors at national level
	VE 3	Donations	Vessel donations	# of donation events from one donor, regardless of the number of tissues obtained
	VE 4	Releases for clinical application, whether distributed or not	Vessels, arteries	# of containers
	VE 5		Vessels, veins	# of containers
	VE 6	Distributed to end user in the country	Vessels, arteries	# of containers
	VE 7		Vessels, veins	# of containers
	VE 8	Distributed to end user in another EU country	Vessels, arteries	# of containers
	VE 9		Vessels, veins	# of containers
	VE 10	Sent to a tissue establishment (transport) in another EU country	Vessels, arteries	# of containers
	VE 11		Vessels, veins	# of containers
	VE 12	Received from a tissue establishment (transport) in another EU country	Vessels, arteries	# of containers
	VE 13		Vessels, veins	# of containers
	VE 14	Exports (non EU)	Vessels, arteries	# of containers
	VE 15		Vessels, veins	# of containers

VE 16	Imports (non EU)	Vessels, arteries		# of containers
VE 17		Vessels, veins		# of containers
VE 18	Application procedures	Applications		# of applications (one surgical procedure, regardless of the # of grafts used)



		MUSCULOSKELETAL TISSUE	NUMBERS	UNITS/EXPLANATIONS	
MUSCULOSKELETAL	MU 1	Donors	Living donors	# of living musculoskeletal tissue donors at national level (including for autologous use of cranial bone and cartilage)	
	MU 2		Deceased donors	# of deceased musculoskeletal tissue donors at national level	
	MU 3	Releases for clinical application, whether distributed or not	Donations	Musculoskeletal tissue donations	# of donation events from one donor, regardless of the number of tissues obtained (including for autologous use of cranial bone and cartilage)
	MU 4		Whole or part of structural/supporting bone	# of pieces	
	MU 5		Tendons (including with bony attachments)/ligaments/fascia	# of pieces	
	MU 6		Osteochondral grafts	# of pieces	
	MU 7		Bone filling material (excluding femoral heads)	# of containers	
	MU 8		Femoral heads	# of containers	
	MU 9		Demineralised bone matrix (including combined with a carrier)	# of containers	
	MU 10		Meniscus	# of pieces	
	MU 11		Other musculoskeletal (e.g. ear ossicles, cranial bone, cartilage)	# of containers	
	MU 12		Distributed to end user in the country	Whole or part of structural/supporting bone	# of pieces
	MU 13			Tendons (including with bony attachments)/ligaments/fascia	# of pieces
	MU 14	Osteochondral grafts		# of pieces	
	MU 15	Bone filling material (excluding femoral heads)		# of containers	
	MU 16	Femoral heads		# of containers	
	MU 17	Demineralised bone matrix (including combined with a carrier)		# of containers	
	MU 18	Meniscus		# of pieces	
	MU 19	Other musculoskeletal (e.g. ear ossicles, cranial bone, cartilage)		# of containers	
	MU 20	Distributed to end user in another EU country		Whole or part of structural/supporting bone	# of pieces
	MU 21		Tendons (including with bony attachments)/ligaments/fascia	# of pieces	
	MU 22		Osteochondral grafts	# of pieces	
	MU 23		Bone filling material (excluding femoral heads)	# of containers	
	MU 24		Femoral heads	# of containers	
	MU 25		Demineralised bone matrix (including combined with a carrier)	# of containers	
	MU 26		Meniscus	# of pieces	
	MU 27		Other musculoskeletal (e.g. ear ossicles, cranial bone, cartilage)	# of containers	
	MU 28	Sent to a tissue establishment (transport) in another EU country	Whole or part of structural/supporting bone	# of pieces	
	MU 29		Tendons (including with bony attachments)/ligaments/fascia	# of pieces	
	MU 30		Osteochondral grafts	# of pieces	
	MU 31		Bone filling material (excluding femoral heads)	# of containers	
	MU 32		Femoral heads	# of containers	
	MU 33		Demineralised bone matrix (including combined with a carrier)	# of containers	
	MU 34		Meniscus	# of pieces	
	MU 35		Other musculoskeletal (e.g. ear ossicles, cranial bone, cartilage)	# of containers	
	MU 36	Received from a tissue establishment (transport) in another EU country	Whole or part of structural/supporting bone	# of pieces	
	MU 37		Tendons (including with bony attachments)/ligaments/fascia	# of pieces	
	MU 38		Osteochondral grafts	# of pieces	
	MU 39		Bone filling material (excluding femoral heads)	# of containers	
	MU 40		Femoral heads	# of containers	
	MU 41		Demineralised bone matrix (including combined with a carrier)	# of containers	
	MU 42		Meniscus	# of pieces	
	MU 43		Other musculoskeletal (e.g. ear ossicles, cranial bone, cartilage)	# of containers	

MU 44	Exports (non EU)	Whole or part of structural/supporting bone	# of pieces
MU 45		Tendons (including with bony attachments)/ligaments/fascia	# of pieces
MU 46		Osteochondral grafts	# of pieces
MU 47		Bone filling material (excluding femoral heads)	# of containers
MU 48		Femoral heads	# of containers
MU 49		Deminerlised bone matrix (including combined with a carrier)	# of containers
MU 50		Meniscus	# of pieces
MU 51		Other musculoskeletal (e.g. ear ossicles, cranial bone, cartilage)	# of containers
MU 52	Imports (non EU)	Whole or part of structural/supporting bone	# of pieces
MU 53		Tendons (including with bony attachments)/ligaments/fascia	# of pieces
MU 54		Osteochondral grafts	# of pieces
MU 55		Bone filling material (excluding femoral heads)	# of containers
MU 56		Femoral heads	# of containers
MU 57		Deminerlised bone matrix (including combined with a carrier)	# of containers
MU 58		Meniscus	# of pieces
MU 59		Other musculoskeletal (e.g. ear ossicles, cranial bone, cartilage)	# of containers
MU 60	Application procedures	Application for orthopaedic/maxillofacial surgery	# of applications (one surgical procedure, regardless of the # of grafts used)
MU 61		Application for dental procedures	# of applications (one surgical procedure, regardless of the # of grafts used)
MU 62		Applications for other treatments (only use if the application does not fit into one of the above categories)	# of applications (one surgical procedure, regardless of the # of grafts used)

NEURONAL TISSUE			NUMBERS	UNITS/EXPLANATIONS
NEURONAL	Donors	Living donors		# of living neuronal tissue donors at national level
		Deceased donors		# of deceased neuronal tissue donors at national level
	Donations	Nerve donations		# of donation events from one donor, regardless of the number of tissues obtained
	Released for clinical application, whether distributed or not	Nerves		# of containers
	Distributed to end user in the country	Nerves		# of containers
	Distributed to end user in another EU country	Nerves		# of containers
	Sent to a tissue establishment (transport) in another EU country	Nerves		# of containers
	Received from a tissue establishment (transport) in another EU country	Nerves		# of containers
	Exports (non EU)	Nerves		# of containers
	Imports (non EU)	Nerves		# of containers
	Application procedures	Applications		# of applications (one surgical procedure, regardless of the # of grafts used)

ADIPOSE TISSUE			NUMBERS	UNITS/EXPLANATIONS
AD	Donors	Living donors		# of living adipose tissue donors at national level
		Deceased donors		# of deceased adipose tissue donors at national level
	Donations	Adipose tissue donations		# of donation events from one donor, regardless of the number of tissues obtained

ADIPOSE	AD 4	Released for clinical application, whether distributed or not	Adipose tissue		# of containers
	AD 5	Distributed to end user in the country	Adipose tissue		# of containers
	AD 6	Distributed to end user in another EU country	Adipose tissue		# of containers
	AD 7	Sent to a tissue establishment (transport) in another EU country	Adipose tissue		# of containers
	AD 8	Received from a tissue establishment (transport) in another EU country	Adipose tissue		# of containers
	AD 9	Exports (non EU)	Adipose tissue		# of containers
	AD 10	Imports (non EU)	Adipose tissue		# of containers
	AD 11	Application procedures	Applications for reconstructive surgery		# of applications (one surgical procedure, regardless of the # of grafts used)
	AD 12		Applications for aesthetic surgery		# of applications (one surgical procedure, regardless of the # of grafts used)
	AD 13		Applications for other treatments (only use if the application does not fit into one of the above categories)		# of applications (one surgical procedure, regardless of the # of grafts used)

PANCREATIC TISSUE			NUMBERS	UNITS/EXPLANATIONS
PANCREATIC	PA 1	Donors	Living donors	# of living pancreatic tissue donors at national level
	PA 2		Deceased donors	# of deceased pancreatic tissue donors at national level
	PA 3	Donations	Pancreatic tissue donations	# of donation events from one donor, regardless of the number of tissues obtained
	PA 4	Released for clinical application, whether distributed or not	Pancreatic islets	# of containers
	PA 5	Distributed to end user in the country	Pancreatic islets	# of containers
	PA 6	Distributed to end user in another EU country	Pancreatic islets	# of containers
	PA 7	Sent to a tissue establishment (transport) in another EU country	Pancreatic islets	# of containers
	PA 8	Received from a tissue establishment (transport) in another EU country	Pancreatic islets	# of containers
	PA 9	Exports (non EU)	Pancreatic islets	# of containers
	PA 10	Imports (non EU)	Pancreatic islets	# of containers
	PA 11	Application procedures	Applications	# of applications (one single procedure, regardless of the # of grafts used)

HEPATIC TISSUE			NUMBERS	UNITS/EXPLANATIONS
HEPATIC	HE 1	Donors	Living donors	# of living hepatic tissue donors at national level
	HE 2		Deceased donors	# of deceased hepatic tissue donors at national level
	HE 3	Donations	Hepatic tissue donations	# of donation events from one donor, regardless of the number of tissues obtained

<b>HEPATIC</b>	HE 4	Releases for clinical application, whether distributed or not	Hepatocytes		# of containers
	HE 5	Distributed to end user in the country	Hepatocytes		# of containers
	HE 6	Distributed to end user in another EU country	Hepatocytes		# of containers
	HE 7	Sent to a tissue establishment (transport) in another EU country	Hepatocytes		# of containers
	HE 8	Received from a tissue establishment (transport) in another EU country	Hepatocytes		# of containers
	HE 9	Exports (non EU)	Hepatocytes		# of containers
	HE 10	Imports (non EU)	Hepatocytes		# of containers
	HE 11	Application procedures	Applications		# of applications (one procedure, regardless of the # of grafts used)

PARATHYROID TISSUE			NUMBERS	UNITS/EXPLANATIONS
<b>PARATHYROID</b>	PR 1	Donors	Living donors	# of living parathyroid tissue donors at national level
	PR 2		Deceased donors	# of deceased parathyroid tissue donors at national level
	PR 3	Donations	Parathyroid tissue donations	# of donation events from one donor, regardless of the number of tissues obtained
	PR 4	Releases for clinical application, whether distributed or not	Parathyroid tissue	# of containers
	PR 5	Distributed to end user in the country	Parathyroid tissue	# of containers
	PR 6	Distributed to end user in another EU country	Parathyroid tissue	# of containers
	PR 7	Sent to a tissue establishment (transport) in another EU country	Parathyroid tissue	# of containers
	PR 8	Received from a tissue establishment (transport) in another EU country	Parathyroid tissue	# of containers
	PR 9	Exports (non EU)	Parathyroid tissue	# of containers
	PR 10	Imports (non EU)	Parathyroid tissue	# of containers
	PR 11	Application procedures	Applications	# of applications (one surgical procedure, regardless of the # of grafts used)

## HAEMATOPOIETIC CELLS ACTIVITY DATA

	COUNTRY	YEAR				
	POTENTIAL FOR ALLOGENEIC DONATION	Registered at 01/01 00:00				
SELF-SUFFICIENCY	SS a 1 # of registered and typed HPC donors					
	SS a 2 # of registered and typed cord blood units available for transplantation of unrelated patients					
	DISTRIBUTION AND EXCHANGE		DISTRIBUTED		IMPORT	EXPORT
	# of unrelated (unit: Cell product from one donor, regardless of the number of donations/containers)	Nationally	From EU countries	To EU countries	From non-EU countries	To non-EU countries
SELF-SUFFICIENCY	SS b 1 HPC from bone marrow for transplantation					
	SS b 2 HPC from peripheral blood for transplantation					
	SS b 3 Peripheral blood mononuclear cells for transplant support (e.g. donor lymphocytes for infusion)					
	SS b 4 Peripheral blood mononuclear cells for other purposes, excluding ATMP (e.g. production of CAR-T cells, NK cells)					
	SS b 5 HPC from cord blood for transplantation					
DONATION CENTRE	DONATION/COLLECTION	AUTOLOGOUS	ALLOGENEIC			
	# of donations (unit: Cell product collected from one donor in one donation procedure - may encompass more than one apheresis session)		Related donor		Unrelated registry donor	
		Paediatric (<18 yr.)	Adult			
	DC a 1 HPC from bone marrow for transplantation					
	DC a 2 HPC from peripheral blood for transplantation					
	DC a 3 Peripheral blood mononuclear cells for transplant support (e.g. donor lymphocytes for infusion)					
	DC a 4 Peripheral blood mononuclear cells for other purposes, excluding ATMP (e.g. production of CAR-T cells, NK cells)					
DC a 5 HPC from cord blood						
DC a 6 Other cells (e.g. bone marrow for other purposes), excluding ATMP						
TISSUE ESTABLISHMENT	RELEASED FOR CLINICAL APPLICATION	AUTOLOGOUS	ALLOGENEIC			
	# released for clinical application, whether distributed or not (unit: Cell product collected from one donor in one donation procedure - may encompass more than one apheresis session)		Related donor	Unrelated registry donor		
	TE a 1 HPC from bone marrow for transplantation					
	TE a 2 HPC from peripheral blood for transplantation					
	TE a 3 Peripheral blood mononuclear cells for transplant support (e.g. donor lymphocytes for infusion)					
	TE a 4 Peripheral blood mononuclear cells for other purposes, excluding ATMP (e.g. production of CAR-T cells, NK cells)					
	TE a 5 HPC from cord blood for transplantation					
	TE a 6 Cord blood for other purposes, excluding ATMP (e.g. production of NK cells, mesenchymals)					
TE a 7 Other cells (e.g. bone marrow for other purposes), excluding ATMP						

TRANSPLANT CENTRES	TRANSPLANT PROCEDURES ASSOCIATED WITH CLINICAL APPLICATION		AUTOLOGOUS	ALLOGENEIC	
				Related donor	Unrelated registry donor
	TC a 1	# of transplants (unit: One transplant procedure with cells obtained from one or more donors)			
	TC a 2	# of recipients (unit: One patient who had at least one transplant procedure during the year concerned)			
	TC a 3	HPC from bone marrow for transplantation			
	TC a 4	HPC from peripheral blood for transplantation			
	TC a 5	HPC from cord blood for transplantation			
	OTHER PROCEDURES ASSOCIATED WITH CLINICAL APPLICATION		AUTOLOGOUS	ALLOGENEIC	
				Related donor	Unrelated registry donor
	TC b 1	# of procedures (unit: One application with cells obtained from one or more donors)			
TC b 2	# of recipients (unit: One patient who had at least one procedure during the year concerned)				
TC b 3	Peripheral blood mononuclear cells for transplant support (e.g. donor lymphocytes for infusion)				
TC b 4	Peripheral blood mononuclear cells for other purposes (e.g. NK cells, Tregs, virus-specific cells), excluding ATMP				
TC b 5	Other cells for other purposes, excluding ATMP				

### MEDICALLY ASSISTED REPRODUCTION ACTIVITY DATA

<b>COUNTRY</b>	<b>YEAR</b>
----------------	-------------

	MAR PARTNER ACTIVITIES	Treatment type			UNIT S/EXPLANATION S
		IUI	IVF/ICSI	Frozen/cryo embryo transfers (FET)	
PA a 1	# of couples treated				# of couples that had at least one treatment cycle intervention (IUI, IVF/ICSI and/or FET) completed
PA a 2	# of treatment cycles without stimulation				# of cycles without ovarian stimulation (includes hormone substituted cycles) that ended up with one of the interventions
PA a 3	# of treatment cycles with stimulation				# of cycles with ovarian stimulation (excludes hormone substituted cycles) that ended up with one of the interventions

PARTNER PROCEDURES	PARTNER GAMETE/EMBRYOS	Numbers (regardless of treatment type)	UNIT S/EXPLANATION S
	PA b 1	# of oocyte retrievals	# of retrieval procedures where at least one oocyte was retrieved
	PA b 2	# of oocytes retrieved	# of oocytes retrieved in total
	PA b 3	# of oocytes cryopreserved	# oocytes cryopreserved in total
	PA b 4	# of sperm collections (including MESA, PESA and TESE)	# of collections, regardless of number of straws and method of collection used
	PA b 5	# of sperm units cryopreserved	# of straws/vials
	PA b 6	# of embryos cryopreserved	# of embryos
	PA b 7	# of embryo transfers (fresh or cryo)	# of procedures, regardless of the number of embryos transferred
	PA b 8	# of embryos transferred (fresh or cryo)	# of embryos
	PA b 9	# of embryos transferred (fresh or cryo) from donated sperm and partner oocytes	# of embryos
PA b 10	# of embryos transferred (fresh or cryo) from donated oocytes and partner sperm	# of embryos	

	DISTRIBUTION AND EXCHANGE OF PARTNER GAMETE S/TISSUE S/EMBRYO S (ACCE S S TO CARE)	TRANSPORT/DISTRIBUTION		IMPORT	EXPORT	UNIT S/EXPLANATION S
		From other EU countries	To other EU countries	From non-EU countries	To non-EU countries	
PA c 1	# of oocytes					# of oocytes
PA c 2	# of sperm units					# of straws/vials
PA c 3	# of embryos					# of embryos
PA c 4	# of ovarian tissues					# of vials/containers
PA c 5	# of testicular tissues (including MESA, PESA and TESE)					# of vials/containers

	DELIVERIES AND LIVE BORN CHILDREN (born during the reporting year regardless of when conceived)	Treatment type		UNIT S/EXPLANATION S
		IUI	IVF/ICSI (fresh or cryo)	
PA d 1	# of deliveries			# of deliveries regardless of the number of children born (including stillborn)
PA d 2	# of live born children			# of infants with any vital signs

	NON-PARTNER GAMETES/EMBRYOS	Numbers (regardless of treatment type)	UNITS/EXPLANATIONS
NP a 1	# of oocyte donors for dedicated and split donation cycles		# of donors (recruited for the specific purpose of donation), regardless of the number of donations
NP a 2	# of oocyte donors of supernumerary oocytes (from partner procedures)		# of donors of supernumerary oocytes from partner procedures, regardless of the number of donations
NP a 3	# of oocyte retrievals intended for donation (dedicated or split)		# of retrieval procedures where at least one oocyte was retrieved
NP a 4	# of oocytes donated (dedicated, split or supernumerary)		# of oocytes
NP a 5	# of oocytes cryopreserved (dedicated, split or supernumerary)		# of oocytes
NP a 6	# of sperm donors		# of donors who provided at least one sample during the year
NP a 7	# of sperm collections		# of collections, regardless of the number of straws
NP a 8	# of sperm units cryopreserved		# of straws/vials
NP a 9	# of embryos donated		# of embryos (supernumerary after partner and non-partner treatments)

	DISTRIBUTION AND EXCHANGE OF NON-PARTNER GAMETES/EMBRYOS (COMMERCIALISATION)	TRANSPORT/DISTRIBUTION		IMPORT	EXPORT	UNITS/EXPLANATIONS
		From other EU countries	To other EU countries	From non-EU countries	To non-EU countries	
NP b 1	# of sperm units					# of straws/vials
NP b 2	# of donated embryos					# of embryos

NON-PARTNER PROCEDURES

	MAR with non partner SPERM donation	Treatment type		UNITS/EXPLANATIONS
		IUI	IVF/CSI	
NP c 1	# of recipients			# women who underwent IUI and/or an embryo transfer involving donated sperm (in the reporting country)
NP c 2	# of treatment cycles with donated sperm			# of cycles, with or without ovarian stimulation, where donated sperm was used
NP c 3	# of partner oocyte retrievals			# of retrieval procedures where at least one oocyte was retrieved
NP c 4	# of embryos cryopreserved			# of embryos (cryopreserved) from donated sperm
NP c 5	# of embryo transfers (fresh or cryo)			# of transfer procedures involving donated sperm, regardless of the number of embryos transferred
NP c 6	# of embryos transferred (fresh or cryo)			# of embryos (transferred) from donated sperm

	MAR with non partner OOCYTE donation	IVF/CSI	UNITS/EXPLANATIONS
NP d 1	# of recipients		# women who underwent at least one embryo transfer involving donated oocytes (in the reporting country)
NP d 2	# of treatment cycles with donated oocytes		# of cycles, stimulated or non-stimulated, where donated oocytes were used
NP d 3	# of partner sperm collections		# of collections, regardless of the number of straws
NP d 4	# of embryos cryopreserved		# of embryos (cryopreserved) from donated oocytes
NP d 5	# of embryo transfers (fresh or cryo)		# of procedures involving donated oocytes, regardless of the number of embryos transferred
NP d 6	# of embryos transferred (fresh or cryo)		# of embryos (transferred) from donated oocytes

	MAR with non partner OOCYTES AND SPERM donation (double donation)	IVF/CSI	UNITS/EXPLANATIONS
NP e 1	# of recipients		# women who underwent at least one embryo transfer involving donated oocytes and sperm (in the reporting country)
NP e 2	# of treatment cycles with donated oocytes and sperm		# of cycles, stimulated or non-stimulated, where donated oocytes and sperm were used
NP e 3	# of embryos cryopreserved		# of embryos (cryopreserved ) from donated oocytes and sperm



NP e 4	# of embryo transfers (fresh or cryo)	# of procedures involving donated oocytes and sperm, regardless of the number of embryos transferred
NP e 5	# of embryos transferred (fresh or cryo)	# of embryos (transferred) from donated oocytes and sperm

	MAR with EMBRYO donation (supernumerary from partner or non-partner treatments)	IVF/ICSI	UNITS/EXPLANATIONS
NP f 1	# of recipients		# women who underwent at least one embryo transfer involving donated supernumerary embryos (in the reporting country)
NP f 2	# of treatment cycles with donated embryos		# of cycles, stimulated or non-stimulated, where donated supernumerary embryos were used
NP f 3	# of embryo transfers (fresh or cryo)		# of procedures involving donated supernumerary embryos regardless of the number of embryos transferred
NP f 4	# of embryos transferred (fresh or cryo)		# of embryos (transferred) from donated supernumerary embryos

	DELIVERIES AND LIVE BORN CHILDREN (during the reporting year regardless of when conceived)	Treatment type		UNITS/EXPLANATIONS
		IUI	IVF/ICSI (fresh or cryo)	
NP g 1	# of deliveries			# of deliveries, regardless of the number of children born (including stillborn)
NP g 2	# of live born children			# of infants with any vital signs

FERTILITY PRESERVATION	FERTILITY PRESERVATION	Numbers	UNITS/EXPLANATIONS
	FP a 1	# of patients who underwent one or more oocyte retrievals	# of patients who underwent at least one oocyte retrieval procedure, regardless of the number of oocytes retrieved
	FP a 2	# of oocyte retrieval procedures	# of oocyte retrieval procedures, regardless of the number of oocytes retrieved
	FP a 3	# of patients who underwent one or more sperm collections (including MESA, PESA and TESE)	# of patients who underwent at least one sperm collection procedure (including MESA, PESA and TESE with mature sperm extracted), regardless of the amount of straws/vials obtained
	FP a 4	# of sperm collection procedures (including MESA, PESA and TESE)	# of sperm collection procedures (including MESA, PESA and TESE with mature sperm extracted), regardless of the amount of straws/vials obtained
	FP a 5	# of patients who underwent an ovarian tissue collection	# of patients who underwent an ovarian tissue collection procedure, regardless of the amount of tissue collected
	FP a 6	# of ovarian tissue collection procedures	# of ovarian tissue collection procedures, regardless of the amount of tissue collected
	FP a 7	# of patients who underwent a collection of immature testicular tissue	# of patients who underwent a collection procedure of immature testicular tissue (i.e. not containing sperm), regardless of the amount of tissue collected
	FP a 8	# of immature testicular tissue collection procedures	# of immature testicular tissue collection procedures, regardless of the amount of tissue collected
	FP a 9	# of patients who underwent an ovarian tissue transplantation	# of patients who underwent an ovarian tissue transplantation, regardless of the number of tissue fragments transplanted

## Glossary of terms

**Application procedure:** clinical use of tissues/cells in a recipient, regardless of the number of grafts applied.

**Batch:** a defined quantity of starting material, packaging material or product processed in one process (or series of processes) so that it can be considered to be homogeneous.

**Cell product from one donor (referring to haematopoietic progenitor cells):** product obtained from one donor in the amount/dosage of haematopoietic progenitor cells needed for one patient for one transplantation procedure/episode/treatment course.

**Container:** receptacle used to store tissues or cells as supplied for clinical use.

Examples:

Musculoskeletal tissue	One individually packaged or supplied graft (e.g. one femoral head, one unit of demineralised bone, one container of bone chips, one femoral strut, one osteochondral allograft, one tendon or part of a tendon).
Ocular tissue	One individually packaged or supplied graft (e.g. one cornea, one piece of sclera).
Cardiac tissues	One individually packaged or supplied graft (e.g. one valve).
Vessels	One individually packaged or supplied graft (e.g. one package containing one or more lengths of vessel).
Amniotic membrane	One container of tissue, regardless of the area of tissue it contains.

**Couple:** two individuals who declare that they are in an intimate physical relationship.

**Cycle:** the process (potentially including medication) that leads to a single collection of gametes (for donation or own use), to the single (one-off) use of gametes or to the transfer of one or more embryos in a single procedure.

**Dedicated oocyte donation:** an oocyte donation in which a specific donor is assigned to a specific recipient, who receives all of the donor's oocytes for a medically assisted reproduction treatment.

**Delivery:** the complete expulsion or extraction from a woman of one or more foetuses, after at least 22 completed weeks of gestation, including both live and stillbirths. A single delivery may result in the birth of one or multiple offspring. If more than one foetus is delivered, it is often recognised as a single delivery with multiple births.

**Distribution:** transportation and delivery of tissues, cells and/or embryos to an organisation responsible for human application in the EU.

**Donor:** an individual, living or deceased, from whom tissue, cells or embryos for human application and/or for other purposes including research, have been retrieved.

**Embryo donation:** the process by which a woman (or couple) donates embryos to enable another woman (or couple) to conceive.

**End user:** person or organisation responsible for the human application of tissues and cells.

**Export:** transportation and delivery of tissues and cells intended for human application to tissue establishments or organisations responsible for human application outside the EU (i.e. in a third country).

**Fertility preservation:** the process of saving or protecting a person's oocytes, sperm and/or, reproductive (ovarian/testicular) tissue so they can use them to try to have biological children later in life.

**Import:** the act of bringing tissues or cells into an EU member state from a country outside the EU (i.e. a third country) for the purpose of human application, further processing or storage.

**Intra-uterine insemination (IUI):** procedure in which processed sperm cells are transferred transcervically into the uterine cavity.

**Intracytoplasmic sperm injection (ICSI):** a procedure in which a single spermatozoon is injected into the oocyte cytoplasm.

**In vitro fertilisation (IVF):** a medically assisted reproduction procedure that involves extracorporeal fertilisation. It includes conventional *in vitro* insemination and intracytoplasmic sperm injection.

**Live birth:** the complete expulsion or extraction from a woman of a product of fertilisation, after 22 completed weeks of gestation which then breathes or shows some other evidence of life, such as a heartbeat, umbilical cord pulsation or definite movement of voluntary muscles, irrespective of whether the umbilical cord has been cut or the placenta is attached. A birth weight of 500 grams or more can be used if gestational age is unknown. Live births refer to the individual newborn; for example, a twin delivery represents two live births.

**Medically assisted reproduction (MAR):** reproduction achieved through various interventions that include *in vitro* handling of both human oocytes and sperm, or of embryos, for the purpose of treating different forms of fertility impairment and infertility. These include, but are not limited to, ovulation induction, ovarian stimulation, ovulation triggering, intra-uterine, intracervical and intravaginal insemination with semen of husband/partner or donor, *in vitro* fertilisation, embryo transfer and intracytoplasmic sperm injection.

**Non-partner procedures:** any medically assisted reproduction method that involves procurement, processing, testing and/or storage of donated human gametes, zygotes, embryos and/or reproductive tissues of donors. Whenever donated gametes are used in a medically assisted reproduction procedure, all cycles, collection procedures and gamete units of both members of the couple should be reported under non-partner procedures.

**Oocyte donation:** the process by which a woman (the donor) donates oocytes to enable another woman (the recipient) to conceive as part of a medically assisted reproduction treatment.

**Ovarian stimulation:** pharmacological treatment with the intention of inducing the development of ovarian follicles. Its purpose is to obtain multiple oocytes at follicular aspiration.

**Partner procedures:** any medically assisted reproduction method that involves procurement, processing, testing and/or storage of human gametes, zygotes, embryos and/or reproductive tissues of couples that have an intimate physical relationship. It does not include medically assisted reproduction procedures involving donated oocytes and/or sperm, i.e. whenever donated gametes are used in a medically assisted reproduction procedure, all cycles, collection procedures and gamete units of both members of the couple should be reported under non-partner procedures.

**Release for clinical application:** the act of certifying compliance of a specific tissue or cells or batch of tissues or cells with the requirements and specifications before storage.

**Sperm donation:** the process by which a man (the donor) donates sperm to enable a woman (the recipient) to conceive as part of a medically assisted reproduction treatment.

**Split oocyte donation:** an oocyte donation in which all the oocytes from one donor are donated for medically assisted reproduction procedures in more than one recipient.

**Supernumerary oocyte (egg sharing)/supernumerary embryo donation:** an oocyte/embryo donation in which a woman who is undergoing a medically assisted reproduction procedure donates some of her oocytes/embryos to the clinic where she is having treatment, so they can be used by another woman (or couple) for medically assisted reproduction.

**Transport:** the act of transferring or conveying of tissues and cells from one place to another within one organisation or between facilities. It may include transport between tissue establishments within the same country or to another EU member state for further processing or storage.